secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001628280-22-022439
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Two Armistice Capital directors resign from Avalo board; CEO Garry Neil appointed Chairman
--------------------------------------------------------------------------------

- Steven Boyd and Keith Maher resigned effective August 8, 2022, not due to any disagreement with the company.
- Armistice Capital Master Fund irrevocably waived its right to appoint two directors to the board.
- CEO Garry Neil replaces Boyd as Chairman; Dr. Magnus Persson remains Lead Independent Director.
- Armistice's CIO expressed continued support for the company and its strategic progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/0001628280-22-022439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022022439/avtx-20220808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-022439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer